Objective To investigate the association between baseline blood ammonia (BLA) and 90-day prognosis in patients with hepatitis B virus (HBV) -related acute-on-chronic liver failure (HBV-ACLF) . Methods A retrospective analysis was performed for the clinical data of 789 patients with HBV-ACLF who were admitted to The Fifth Medical Center of Chinese PLA General Hospital from January2013 to December 2016, and the association between baseline BLA and 90-day prognosis was analyzed. The Cox regression risk model was used for multivariate analysis. The Kaplan-Meier survival curve was used to analyze the 90-day survival rate of patients with different levels of baseline BLA, and the log-rank test was used for comparison. Results The Cox multivariate regression analysis showed that BLA was independently and positively correlated with the risk of 90-day death in HBV-ACLF patients (Model 2: hazard ratio = 1. 007, 95%confidence interval: 1. 005-1. 010, P < 0. 00001) . The log-rank test indicated that in the patients without hepatic encephalopathy (HE) , the BLAhigh group had the highest 90-day cumulative mortality rate, followed by the BLAmid group and the BLAlow group (P = 0. 0023) ; among the patients with HE, the BLAhigh group had a significantly higher 90-day cumulative mortality rate than the other two groups (P= 0. 012) , while there was no significant difference in 90-day cumulative mortality rate between these two groups (P = 0. 18) . Conclusion Baseline BLA is independently and positively correlated with the risk of 90-day death in HBV-ACLF patients, and it may have a certain clinical value in treatment and prognostic evaluation.
[1]WIJDICKS EF.Hepatic Encephalopathy[J].N Engl J Med, 2016, 375 (17) :660-1670.
|
[2]TAPPER EB, JIANG ZG, PATWARDHAN VR.Refining the ammonia hypothesis:A physiology-driven approach to the treatment of hepatic encephalopathy[J].Mayo Clin Proc, 2015, 90 (5) :646-658.
|
[3]JIA B, YU ZJ, DUAN ZF, et al.Hyperammonaemia induces hepatic injury with alteration of gene expression profiles[J].Liver Int, 2014, 34 (5) :748-758.
|
[4]ALBILLOS A, LARIO M, ALVAREZ-MON M.Cirrhosis-associated immune dysfunction:Distinctive features and clinical relevance[J].J Hepatol, 2014, 61 (6) :1385-1396.
|
[5] SHAWCROSS DL, WRIGHT GA, STADLBAUER V, et al.Ammonia impairs neutrophil phagocytic function in liver disease[J].Hepatology, 2008, 48 (4) :1202-1212.
|
[6]JALAN R, de CHIARA F, BALASUBRAMANIYAN V, et al.Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension[J].J Hepatol, 2016, 64 (4) :823-833.
|
[7]LATTANZI B, D'AMBROSIO D, MERLI M.Hepatic encephalopathy and sarcopenia:Two faces of the same metabolic alteration[J].J Clin Exp Hepatol, 2019, 9 (1) :125-130.
|
[8]DASARATHY S, MERLI M.Sarcopenia from mechanism to diagnosis and treatment in liver disease[J].J Hepatol, 2016, 65 (6) :1232-1244.
|
[9]YOU S, RONG Y, ZHU B, et al.Changing etiology of liver failure in 3, 916 patients from northern China:A 10-year survey[J].Hepatol Int, 2013, 7 (2) :714-720.
|
[10]QIN G, SHAO JG, ZHU YC, et al.Population-representative Incidence of acute-on-chronic liver failure:A prospective cross-sectional study[J].J Clin Gastroenterol, 2016, 50 (8) :670-675.
|
[11]Chinese Society of Hepatology, Chinese Medical Association;Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会传染病学分会.慢性乙型肝炎防治指南 (2015更新) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.
|
[12]Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association;Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association.Guideline for diagnosis and treatment of liver failure (2018) [J].J Clin Hepatol, 2019, 35 (1) :38-44. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重症肝病与人工肝学组.肝衰竭诊治指南 (2018年版) [J].临床肝胆病杂志, 2019, 35 (1) :38-44.
|
[13]SARIN SK, CHOUDHURY A.Acute-on-chronic liver failure:terminology, mechanisms and management[J].Nat Rev Gastroenterol Hepatol, 2016, 13 (3) :131-149.
|
[14]ZHANG DJ, ZHOU B, HOU JL.Research progress in prognostic models of acute-on-chronic liver failure[J].J Clin Hepatol, 2018, 34 (6) :1351-1356. (in Chinese) 张东敬, 周彬, 侯金林.慢加急性肝衰竭预后模型的研究进展[J].临床肝胆病杂志, 2018, 34 (6) :1351-1356.
|
[15]SHALIMAR, SHEIKH MF, MOOKERJEE RP.et al.Prognostic role of ammonia in patients with cirrhosis[J].Hepatology, 2019.
|
[16]RAVI S, BADE KS, HASANIN M, et al.Ammonia level at admission predicts in-hospital mortality for patients with alcoholic hepatitis[J].Gastroenterol Rep (Oxf) , 2017, 5 (3) :232-236.
|
[17]PATWARDHAN VR, JIANG ZG, RISECH-NEIMAN Y, et al.Serum ammonia in associated with transplant-free survival in hospitalized patients with acutely decompensated cirrhosis[J].J Clin Gastroenterol, 2016, 50 (4) :345-350.
|
[18]SUN C, ZHAO JY, LU ZM.Research on regulating the blood ammoniathrough silencing Rhc glycoprotein by small interfering RNA[J].Trauma Crit Care Med, 2019, 7 (1) :16-19. (in Chinese) 孙晨, 赵骥越, 卢再鸣.小干扰RNA通过沉默Rhc糖蛋白调节血氨研究[J].创伤与急危重医学, 2019, 7 (1) :16-19.
|
[19]CORDOBA J, VENTURA-COTS M, SIMON-TALERO M, et al.Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF) [J].J Hepatol, 2014, 60 (2) :275-281.
|
[20]ROMERO-GOMEZ M, MONTAGNESE S, JALAN R.Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure[J].J Hepatol, 2015, 62 (2) :437-447.
|
[21]SHAWCROSS DL, WRIGHT GA, STADLBAUER V, et al.Ammonia impairs neutrophil phagocytic function in liver disease[J].Hepatology, 2008, 48 (4) :1202-1212.
|
[22]LIU CP, YU ZJ.Study on L-Ornithine-L-Aspartate in the treatment of acute-on-chronic liver failure[J].Chin J Hepatol, 2011, 19 (1) :63-64. (in Chinese) 刘翠萍, 余祖江.全程门冬氨酸鸟氨酸治疗延缓乙型肝炎病毒相关慢加急性肝衰竭的进展[J].中华肝脏病杂志, 2011, 19 (1) :63-64.
|
1. | 朱宏坤,戴芳芳,钱世宁. 血必净注射液对行连续性肾脏替代疗法的多器官功能障碍综合征患者凝血功能的影响. 哈尔滨医科大学学报. 2024(01): 75-79 . ![]() | |
2. | 肖晶晶. 局部枸橼酸抗凝联合CRRT治疗脓毒症合并急性肾衰竭的临床疗效及对患者凝血功能的影响. 延边大学医学学报. 2024(05): 534-537 . ![]() | |
3. | 王娟,张丽萍,丁童,卫淑润,翁志华. 局部枸橼酸抗凝血液净化技术在ICU造血干细胞移植后弥漫性肺泡出血患者治疗中应用价值. 临床军医杂志. 2023(05): 522-524 . ![]() | |
4. | 孙卫和,许伟伟,冒秀宏,汪涛. 局部枸橼酸抗凝在重症急性肾损伤患者连续性肾脏替代治疗中的应用. 中外医疗. 2023(18): 129-132 . ![]() | |
5. | 赵志强,孟鹏飞,石正松,陈亚君,肖宏涛. 枸橼酸抗凝在脓毒症伴高危出血行连续性肾脏替代治疗患者中的应用效果. 医药论坛杂志. 2023(19): 14-18 . ![]() | |
6. | 李一青,白银果,沙莎. 连续性静脉-静脉血液滤过透析和局部枸橼酸抗凝在重症患者乳酸升高时应用的有效性和安全性研究. 贵州医药. 2023(11): 1704-1705 . ![]() | |
7. | 张妍,荣阳,张芳. CRRT治疗肾衰竭合并顽固性心力衰竭的临床效果. 中西医结合心脑血管病杂志. 2022(02): 285-288 . ![]() | |
8. | 张竞葳,田敏,余建斌. 局部枸橼酸抗凝应用于维持性血液透析合并消化道出血患者的疗效观察. 现代医学与健康研究电子杂志. 2022(13): 130-134 . ![]() | |
9. | 陈伟玲,邓虹,黄颖妍,李乐,张洪举. 局部枸橼酸抗凝在连续性肾替代疗法治疗中的效果及安全性指标的变化. 北方药学. 2022(05): 116-119 . ![]() | |
10. | 吴允东,江海娇,张伟,曹迎亚,杨尚志,周伟. 不同抗凝方案用于心脏术后患者连续性肾脏替代治疗中的效果. 皖南医学院学报. 2022(05): 436-439+443 . ![]() | |
11. | 严海燕,黄雪敏,李大亮,岑树坤,蒋林青. 局部枸橼酸抗凝在重症急性肾损伤患者连续性肾脏替代治疗中的应用分析. 实用中西医结合临床. 2022(17): 31-33+37 . ![]() | |
12. | 金源源,诸炳骅,费雪洁,王倩. 局部枸橼酸抗凝在肝衰竭患者连续性肾脏替代治疗中的应用. 临床肝胆病杂志. 2021(01): 200-203 . ![]() | |
13. | 胡新,毛智,周飞虎. 枸橼酸抗凝在重症患者连续血液净化中的应用进展. 武警医学. 2021(01): 78-81 . ![]() | |
14. | 杨向莎,杨福燕,张瑞霞,张军. 改良式枸橼酸钠与低分子量肝素在急性肾损伤CRRT中的抗凝效果比较. 临床医学研究与实践. 2021(20): 46-49 . ![]() | |
15. | 冉梦晓,陈辉,郑浩天. 枸橼酸局部抗凝技术在血液透析中的应用进展. 中国医药. 2021(07): 1113-1116 . ![]() | |
16. | 杨妮娜,李之诉,杨禄,陈王峰. RCA-CRRT治疗中滤器后离子钙与体内离子钙的相关性. 现代实用医学. 2021(08): 993-995 . ![]() | |
17. | 焦清海,郑丽环,张雪梅,王征,杜菲,陈亮. 局部枸橼酸抗凝在危重症患者持续肾脏替代疗法中的临床应用. 河北医科大学学报. 2021(10): 1144-1148 . ![]() | |
18. | 王敬文. 枸橼酸与肝素抗凝对重症血液净化患者临床指标和安全性的影响比较. 中外医学研究. 2021(32): 40-43 . ![]() | |
19. | 冯菁,李和文,张兴凯,王建华,张作鹏,郭燕蓉,任航奇. 肝衰竭患者行局部枸橼酸抗凝连续性肾脏替代治疗时发生枸橼酸蓄积的影响因素分析. 临床和实验医学杂志. 2021(22): 2402-2406 . ![]() | |
20. | 李杨,由丽丽. 连续性肾脏替代治疗脑出血合并急性肾损伤患者中应用局部枸橼酸抗凝治疗的有效性及安全性. 中国医药指南. 2020(36): 89-90 . ![]() |